The observational retrospective cohort Study on HEalthcare Resource utiLization (HCRU) related to exacerbatiOns in patients with COPD (SHERLOCK; D5980R00014) evaluated exacerbation-related HCRU and costs using the U.K. National Health Service Greater Glasgow and Clyde Health Board data. Patients (≥40 years) with COPD were stratified by exacerbations one year before the index date: Group A (none), B (1 moderate), C (1 severe) and D (≥2 moderate and/or severe). All-cause and COPD-related HCRU and costs were assessed over 36 months. Adjusted rate ratios (RRs) or relative costs versus Group A were estimated using generalized linear models with appropriate distributions and link functions. The study included 22 462 patients (Group A, n = 7788; B, n = 5151; C, n = 250 and D, n = 9273). At 12 months, RRs (95% CI) versus Group A for all-cause and COPD-related HCRU, respectively, were highest in Groups C (1.28 [1.18, 1.39] and 1.18 [1.09, 1.29]) and D (1.26 [1.23, 1.28] and 1.29 [1.26, 1.31]). General practitioner and outpatient visits, and general ward stays/days accounted for the greatest COPD-related HCRU. All-cause and COPD-related relative costs (95% CI) versus Group A at 12 months, respectively, were 1.03 (0.94, 1.12) and 1.06 (0.99, 1.13) in Group B; 1.47 (1.07, 2.01) and 1.54 (1.20, 1.97) in Group C; 1.47 (1.36, 1.58) and 1.63 (1.54, 1.73) in Group D. Increased HCRU and costs in patients with exacerbation histories persisted at 36 months, demonstrating the sustained impact of exacerbations. The study suggests the importance of management and prevention of exacerbations through intervention optimization and budgeting by payers for exacerbation-related costs.
|Number of pages||9|
|Journal||COPD: Journal of Chronic Obstructive Pulmonary Disease|
|Early online date||19 Dec 2022|
|Publication status||E-pub ahead of print - 19 Dec 2022|
Medical writing support, under the direction of the authors, was provided by Sara Cameron, MPhil, CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca in accordance with Good Publication Practice (GPP 2022) guidelines [Citation28]. All authors were involved in the design and conduct of the study and in the interpretation of the data. All authors were involved in the writing of the manuscript and the final decision to submit to COPD: Journal of Chronic Obstructive Pulmonary Disease.
This study was sponsored by AstraZeneca. AstraZeneca authors were involved in the design of the study; in the analysis, and interpretation of the data; in the writing of the report; and in the decision to submit the article for publication.
Data Availability StatementSupplemental data for this article can be accessed online at https://doi.org/10.1080/15412555.2022.2136065
- chronic obstructive pulmonary disease
- exacerbation history
- exacerbation severity
- healthcare costs
- healthcare resource utilization